Measurement of ^153Sm-EDTMP bone uptake by whole-body scintigraphy and its application to indivdualized treatment dosimetry of bone metastasis

To calcultae a safe and effective ^153Sm-EDTMP therapy dose,a wholebody scintigraphy technique for prospective individual dosimetry was developed and the results were compared with 5h urine collection metohd in 20 patients with bons metastases,Anterior and posterior whole-body images were obtained 10 min and 5h after intravenous injection of 740 MBq ^153Sm-EDTMP and the bone uptake value was determined,There is a colse correlation between the bone uptake value obtained from the whole-body scintigraphy and 5h urine collection method (r=0.93) ,The radiation absorption dose to red marrow was limited to 1.4Gy and the administered activity calculated from bone uptake value by whole-body scintigraphy was 1.40-2.27 GBq (mean 1.90 GBq),If the activity was calculated according to the standard body weight of 37 MBq.kg^-1,the administered activity would be 1.75-2.41 GBq(mean 2.18),the radiation absortion dose to red marrow would be 1.37-2.27 Gy(mean 1.63Gy),but at these doses significant myelotoxicity would be anticipated,thus emphasizing the need for individual prospective dosimetry.     

89Sr、153Sm内照射治疗骨转移癌引起骨痛的剂量研究

对^89Sr或^153Sm-EDTMP治疗的72例(74例次)骨转移癌病人的疗效、内照射靶器官的吸收剂量以及剂量响应关系进行了分析评价。结果表明,经^89Sr治疗的3l例(33例次)骨转移癌病人,治疗后骨痛反应属Ⅰ级者15例次,Ⅱ级者14例次,共29例次,占87．88％;Ⅲ级者4例次,占12．12％。未发现治疗后骨痛反应分级与^89Sr用量有明显关系;经^153Sm-EDTMP治疗的41例骨转移癌病人,治疗后骨痛反应属Ⅰ级者19例,Ⅱ级者18例,共37例,占90．24％;Ⅲ级者4例,占9．76％。未发现治疗后骨痛反应分级与^153Sm-EDTMP用量有明显关系。结果提示,亲骨性放射性药物^89Sr、^153Sm-EDTMP姑息治疗骨转移癌的骨痛效果显著。     

Preparation and bio-distribution of 153Sm-HEDTMP as a radiopharmaceutical for bone metastases

1 Introduction Metastases to skeleton from prostate, breast, andlung cancer are frequent in clinical practice. The pal-liation of patients with extreme pain of bone metasta-ses was of primary importance in clinical managementof patients with advanced cancer. Based on concentra-tion at sites of increased bone turnover, ra-dio-therapeutics was an effective alternative to con-ventional therapies. 153Sm-EDTMP (ethylene diaminetetramethylene phosphonate) has been developed topalliate su…     

153Sm-EDTMP诱发骨肉瘤细胞凋亡的荧光显微镜形态和增生抑制研究

通过荧光显微镜观察,发现骨肉瘤细胞受到＾１５３Ｓｍ内照射作用后,可诱发明显的核断裂和核固缩,以及以凋亡小体形成为特征的瘤细胞凋亡。同时揭示,经＾１５３Ｓｍ－ＥＤＴＭＰ辐照后可呈现出对骨肉瘤细胞的增生抑制效应。并随着辐射时间的延长,增生抑制率亦随之增升。     

32P-GTMS治疗前列腺增生的动物研究及初步临床应用探讨

采用3 2 P -GTMS治疗前列腺增生 ,能抑制前列腺间质细胞增生 ,改善排尿障碍症状。 (1)取 7条雄性健康草犬 ,以 2 5mg/kg丙睾每周 3次肌肉注射 ,持续 30d ,制成前列腺增生模型。 5条草犬模型在超声引导下注入 9.2 5— 74MBq/mL不等的3 2 P -GTMS ,分别于 30、6 0、90d活检 ,了解前列腺破坏、缩小数据。 2条草犬模型不予3 2 P -GTMS治疗 ,维持肌肉注射丙酸睾酮 ,直至治疗草犬疗效观察结束后作前列腺增生后缩小率比较。 (2 )根据草犬模型提供资料对 34例前列腺增生患者也行在超声引导下穿刺 ,注入3 2 P -GTMS 111± 18.5MBq ,分别于 30、6 0、90d测定前列腺容积 ,尿流率 ,残余尿及I -PSS评分结果 ,部分患者作活检病理。表明 7条草犬经注射丙酸睾酮后 30d ,前列腺平均增大 2倍以上。经3 2 P -GTMS治疗的 5条前列腺增生模型草犬的前列腺均出现前列腺细胞变性 ,炎性细胞浸润。当3 2 P -GTMS用量大于 13.88MBq/mL时呈显效结果 ,90d平均缩小率 >4 3.4 %,而对照组平均缩小率 <13%。 34例前列腺增生患者治疗 90d后前列腺缩小 17%,最大尿流率增加 4 1%,残余尿减少 74 %,I -PSS评分下降 31%,(P <0 .0 1)。病理切片结果显示 :增生前列腺细胞变性 ,萎缩。实验结果提示 ,采用B超引导下穿刺 ,在增生的前列腺内注入3 2 P